Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic Paraplegia (FRAME)

3 november 2026 uppdaterad av: IRCCS Eugenio Medea

Flexibility, Resistance, Aerobic, Movement Execution (FRAME) Training Program to Improve Gait Capacity in Adults With Hereditary Spastic Paraplegia: Protocol for a Single-cohort Feasibility Trial

Hereditary Spastic Paraplegia (HSP) is a group of inherited neurological disorders that cause progressive weakness and stiffness (spasticity) in the legs, reducing balance and walking ability. At present, there are no structured rehabilitation programs specifically designed to improve walking in people with HSP.

This study aims to find out whether a structured, therapist-guided exercise program called FRAME training can be delivered successfully to people with HSP, and whether it may help improve their walking. The program combines flexibility, muscle strengthening, motor control, balance and aerobic exercises. At the end of the program, participants receive a written manual and video tutorials to help them keep exercising at home.

Studieöversikt

Status

Aktiv, inte rekryterande

Detaljerad beskrivning

Hereditary Spastic Paraplegia (HSP) is a heterogeneous group of inherited neurological disorders. It is characterized by progressive lower-limb weakness and spasticity that significantly impair walking endurance and speed. Several interventions have been studied for specific impairments, but there are still no comprehensive, structured neurorehabilitation programs designed to improve walking function in this population. This study explores a composite training approach (FRAME) that addresses the main factors limiting gait in HSP: reduced flexibility, muscle weakness, impaired motor control and balance, and low aerobic capacity.

Participants attend 10 to 16 therapist-guided sessions of 60 to 120 minutes, once or twice a week according to individual preferences and capabilities. Each session may include four components:

  1. Flexibility: stretching of the muscles typically affected by spasticity (triceps surae, adductors, rectus femoris, hamstrings), combined with biphasic high-frequency sensory electrical stimulation (100 Hz, 200 µs, intensity just below motor threshold, 30 minutes) to reduce muscle tone and enhance mobility.
  2. Resistance training and balance: strengthening of the muscles typically weakened in HSP, especially the proximal hip and trunk muscles. Core stability and resistance exercises are performed in sitting or standing under mild instability to promote muscle activation, balance and coordination.
  3. Movement execution and balance: gait training based on motor learning principles (repetitive task-oriented practice, variable practice, graded practice), with standing balance challenges and varied walking tasks (fast, slow, sideways and backward walking, stair climbing).
  4. Aerobic training: high-intensity interval training (HIIT), which has been shown to produce greater cardiovascular benefits than moderate-intensity exercise at a lower perceived effort. HIIT includes a 5-minute warm-up, two sets of 10 intervals (30 seconds high intensity / 30 seconds passive rest) with 5 minutes of rest between sets, and a 5-minute cool-down. The exercise mode (walking, running, cycling or squatting) is chosen to suit each participant.

At the end of the program, participants receive a transfer package (written manual and video tutorials) to support long-term home exercise.

This study is expected to give clinicians insight into whether a comprehensive, clinically oriented program can be delivered to adults with HSP and how much it may help them walk better. It will also inform future translational research in this field.

Studietyp

Interventionell

Inskrivning (Faktisk)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Lombardy
      • Bosisio Parini, Lombardy, Italien, 23842
        • Scientific Institute, IRCCS E. Medea, Department of Bosisio Parini, Lecco, Italy.
    • Veneto
      • Pieve di Soligo, Veneto, Italien, 31053
        • Scientific Institute, IRCCS E. Medea, Department of Pieve di Soligo, Treviso, Italy

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults diagnosed with Hereditary Spastic Paraplegia.
  • Presence of any functional deficit in the lower limbs that affects walking, such as muscle weakness, hypertonia, or balance issues.
  • Ability to walk without the need for physical contact with another person, as defined by a Functional Ambulation Category score of 3 or higher.
  • Ability to understand simple instructions, comprehend the purpose of the study, willingness to participate and undergo at least 10 treatment sessions, eligible and willing to sign the informed consent.

Exclusion Criteria:

  • Botulinum toxin or surgery to treat lower limb hypertonia in the six months prior to enrollment in the study.
  • Contraindications for moderate physical activity, such as stretching exercises, muscle strength training, and aerobic capacity training.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: HSP Cohort

The whole cohort of HSP patients will receive the same comprehensive neurorehabilitation program aiming at improving gait capabilities (speed and endurance). The content and the dose of the treatment will be personalized according to patient's specific needs and preferences.

Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.

Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.

Movement execution training: gait training according to motor learning principles.

Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurotrophic factors).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Feasibility (recruitment rate).
Tidsram: From study start up to 24 months.

Study feasibility in terms of achieving sufficient recruitment rate, defined as the enrollment of 20 patients within 24 months from the start of the study.

From study start up to 24 months.
Feasibility (adherence rate).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Study feasibility in terms of achieving adequate adherence to the treatment plan, defined as completing at least 75% of the scheduled treatment sessions, and in any case a minimum of 10 treatment sessions.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1).
Feasibility (retention rate).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Study feasibility in terms of achieving sufficient patient retention, defined as at least 75% of the enrolled patients completing the study with adequate adherence to the treatment.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1).
Feasibility (safety).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Study feasibility in terms of absence of any serious adverse event related to patient participation in the study.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Six Minute Walking Test (6MWT).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The 6MWT is a clinical assessment of gait endurance, by measuring the distance covered (metres) while walking on a straight even path (30 meters) for six minutes. According to original instructions, the patient is asked to walk along the path as fast as possible, taking turns at the edges of the path. Patients are allowed to walk autonomously or with assistive devices and to rest by standing.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Ten Metre Walk Test (10MWT).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The 10MWT is used to assess walking speed in meters/second (m/s) over a short distance. The total time taken to walk six meters (the central portion of a 10-meter walkway) is recorded to the nearest hundredth of a second. 6 meters is then divided by the total time taken to ambulate and recorded in m/s.

Two trials at comfortable pace are performed, followed by two trials at fast pace. Averages (one for comfortable pace, one for fast pace) are recorded.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Passive range of motion.
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

An inclinometer will be used to measure the passive range of motion for ankle dorsiflexion, knee flexion, hip abduction, and hip extension, on both sides.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Hereditary Spastic Paraplegia - Self Notion and Perception Questionnaire (HSP-SNAP).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

HSP-SNAP is a questionnaire used to assess the self-perception of individuals diagnosed with hereditary spastic paraplegia (HSP).

HSP-SNAP includes 12 questions, with 2 items dedicated to each symptom dimension (stiffness, weakness, imbalance, reduced endurance, fatigue, and pain). Each pair of items for a given dimension includes both positive and negative responses to prevent automatic answers. The HSP-SNAP employs a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree). To account for both positive and negative items, scoring is as follows: for items with a positive tone, the score is calculated as "patient's score minus 1" (pt score-1); for negative items, the score is "5 minus the patient's score" (5-pt score). The overall score is the sum of all item scores, ranging from 0 to 48. A higher score indicates better well-being and milder symptoms.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Functional Reach Test (FRT).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

FRT evaluates dynamic balance while standing. Patient is asked to stand with one shoulder flexed at 90 degrees and the hand making a fist, and then to bend forward up to the limit of balance, right before taking a step to prevent falling. A horizontal ruler taped on the wall is used to measure the difference in position of the head of the third metacarpal bone from starting to end position. Patients are not allowed to touch the wall or rotate the trunk while bending forward.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Five times Sit-to-Stand (5TSTS).
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The 5TSTS test is an assessment to evaluate lower body strength, balance, and functional mobility. The test involves the participant sitting in a chair, then standing up and sitting down five times as quickly as possible, without using their arms for assistance. The time taken to complete the five repetitions is recorded.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
modified Spastic Paraplegia Rating Scale (mSPRS)
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

The mSPRS is a clinical assessment tool used to evaluate the severity and progression of symptoms in individuals with hereditary spastic paraplegia. The scale measures aspects such as spasticity, mobility, and functional abilities related to walking, balance, and limb function.

The mSPRS has a scoring range from 0 to 28, with higher scores on the mSPRS indicating more severe symptoms and greater impairment in motor function and spasticity.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Stabilometric platform.
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

With the patient standing over a stabilometric platform, two kinematic assessments will be performed: (1) static stance, by standing for 30 seconds with eyes open and 30 seconds with eyes closed; (2) limits of stability, by bending with the body in different direction, displacing the centre of mass towards anterior, posterior, and lateral targets projected on a screen in front of the patient.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).
Isometric strength.
Tidsram: Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

A dynamometer will be used to measure isometric strength for ankle dorsiflexors, ankle plantarflexors, knee extensors, knee flexors, hip extensors, hip flexors, hip abductors, on both sides.

Enrolment (T0), end of treatment five to ten weeks after T0 (T1), follow-up 12 weeks after T1 (T2).

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Leonardo Boccuni, PhD, Scientific Institute, IRCCS E. Medea, Department of Conegliano, Treviso, Italy.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 december 2024

Primärt slutförande (Beräknad)

1 januari 2027

Avslutad studie (Beräknad)

30 april 2027

Studieregistreringsdatum

Först inskickad

12 december 2024

Först inskickad som uppfyllde QC-kriterierna

18 december 2024

Första postat (Faktisk)

19 december 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Anonymized individual participant data will be shared with other researchers upon reasonable request.

Tidsram för IPD-delning

Start Date: June 2027. End Date: June 2037.

Kriterier för IPD Sharing Access

Any researcher accredited by non-profit clinical and research centre.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • ANALYTIC_CODE
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera